Among them, fully human monoclonal antibody secukinumab (Cosentyx), a product of Novartis International AG, targeting human IL-17A cytokine, is available for treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis [23,24,25]. This evidence concerns the gene IL17A and psoriasis.